News
Is it safe to start dabigatran in the first days after ischemic stroke?
For patients after cardioembolic ischemic stroke (iCMP), starting anticoagulant therapy is crucial, but it is not strictly defined how many days after iCMP it is ideal to begin. The article provides a summary of a recent observational study that investigated the appropriate timing of starting dabigatran in patients with non-valvular atrial fibrillation (NVAF) after their first iCMP who were treated with intravenous thrombolysis or endovascular thrombectomy.
Is the combination of tiotropium/olodaterol proven more effective in reducing the risk of clinically significant worsening of COPD compared to monotherapy?
Given the heterogeneity of chronic obstructive pulmonary disease (COPD), the use of a composite…
Impact of Chronic Urticaria on Patients' Quality of Life and Society
An international team of dermatologists has mapped out the impact of chronic urticaria on various…
Perioperative substitution therapy in patients with vWD must be tailored
Even in cases of von Willebrand disease (vWD), available data supports the need for individualized…
Another Piece of the Puzzle for More Accurate Dosing of Clotting Factors in von Willebrand Disease
A study published last year in the Journal of Thrombosis and Haemostasis presents the results of…
The Position of Lurasidone in Schizophrenia Therapy − Current Conclusions and Consensus of the Expert Panel
Lurasidone is an antipsychotic belonging to the group of serotonin and dopamine antagonists (SDA)…
Recommendations for Nutrition of Patients at Risk of or with Pressure Ulcers
Nutrition plays a crucial role in the prevention and treatment of pressure ulcers. In 2019,…
Classification and Management of Chronic Wounds
Chronic wounds are common comorbidities that increase the morbidity and mortality of patients.…
Efficacy of Panitumumab in the Treatment of Refractory mCRC
A meta-analysis of 7 clinical trials showed that panitumumab therapy demonstrates a higher overall…
Current Recommendations for Using SGLT2 Inhibitors in Patients with Renal or Cardiovascular Risk
Type 2 diabetes mellitus (DM2) is a serious chronic metabolic disease whose prevalence has been…